Gain Therapeutics, Inc.
GANX
$1.80
$0.063.45%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 16.00% | 44.91% | -102.86% | 15.03% | -0.12% |
| Total Depreciation and Amortization | -3.13% | 0.00% | 12.94% | -26.72% | 54.67% |
| Total Amortization of Deferred Charges | 0.00% | 9.09% | -8.33% | 0.00% | -7.69% |
| Total Other Non-Cash Items | 191.51% | -76.21% | 13,675.26% | -102.31% | -43.03% |
| Change in Net Operating Assets | 67.75% | -283.50% | 151.75% | 130.22% | -26,426.92% |
| Cash from Operations | 43.15% | -5.56% | -60.50% | 36.64% | -42.70% |
| Capital Expenditure | -- | 100.00% | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -100.00% | -32.96% | -3.92% | 62.84% |
| Cash from Investing | -- | -100.00% | -33.68% | -3.92% | 62.90% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 1.30% | -4.52% | 3.49% | -1.33% | 0.00% |
| Issuance of Common Stock | 180.79% | -91.73% | 6,270.17% | -98.35% | 6,000.06% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | 185.99% | -91.94% | 6,983.68% | -101.53% | 7,008.25% |
| Foreign Exchange rate Adjustments | -225.55% | 2,822.14% | 102.96% | -191.58% | 434.16% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 65.90% | -177.59% | 644.53% | -115.36% | 467.43% |